Telomir Pharmaceuticals Files 8-K Report
Ticker: TELO · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1971532
Sentiment: neutral
Topics: 8-K, disclosure, other-events
TL;DR
Telomir Pharma dropped an 8-K, but details are scarce. Watch for more info.
AI Summary
On January 28, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding the nature of these events, any associated financial figures, or involved parties were provided in the excerpt.
Why It Matters
This 8-K filing signals a material event for Telomir Pharmaceuticals, Inc., requiring disclosure to investors. The lack of specific details in the provided excerpt necessitates further investigation to understand the implications.
Risk Assessment
Risk Level: medium — The filing of an 8-K often indicates significant corporate events, but the lack of specific details in this excerpt creates uncertainty about the nature and impact of these events.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- January 28, 2025 (date) — Date of earliest event reported
- Florida (location) — State of Incorporation
- Miami (location) — City of Principal Executive Offices
FAQ
What specific event(s) are being reported under "Other Events"?
The provided excerpt does not specify the nature of the "Other Events" being reported by Telomir Pharmaceuticals, Inc.
Are there any financial implications associated with this 8-K filing?
The excerpt does not mention any specific dollar amounts or financial transactions related to the reported event.
When was this 8-K filing officially submitted?
The filing was submitted on January 28, 2025.
What is the principal business of Telomir Pharmaceuticals, Inc.?
Telomir Pharmaceuticals, Inc. is in the business of Pharmaceutical Preparations, with SIC code 2834.
Where are Telomir Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida.
Filing Stats: 763 words · 3 min read · ~3 pages · Grade level 16 · Accepted 2025-01-28 07:30:12
Filing Documents
- form8-k.htm (8-K) — 41KB
- 0001493152-25-003909.txt ( ) — 213KB
- telo-20250128.xsd (EX-101.SCH) — 3KB
- telo-20250128_lab.xml (EX-101.LAB) — 33KB
- telo-20250128_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Dated: January 28, 2025 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer